REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx1 and PlanB2 studies, the 16th St. Gallen International Breast ...

In this study, we reviewed the clinical, morphologic, and immunophenotypic data of DCIS cases sent for Oncotype DCIS at our institution, and analyzed whether any features were predictive of the ...

- Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test's impact on clinical practice with ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

(NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests.

Changes in bone mineral density with adjuvant aromatase inhibitor treatment and breast cancer recurrence. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not ...

MADISON, Wis., February 03, 2026--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its ...

REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna ...

The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by Georgetown Lombardi ...